Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Brilacidin for oral mucositis, the drug referred here as B-OM, is an unmet need against a debilitating and deadly side effect of radiation and other immune compromising therapies. The bar for approval is very low. B-OM treatment resulted in up to 80% prevention in some subgroups and an overall prevention of more than 20% overall when compared to the study placebo group. B-OM is nearly a lock for approval and IPIX is in the process of applying for FDA breakthrough therapy designation.

Some big pharma will want this drug; it’s only a matter of which BP, how many other Brilacidin indications BP might want in addition to B-OM, and final valuation and license/partner structure.